CanSino Biologics Inc. (SEHK: 6185)
Health Care · Biotechnology · CN
HK$29.48
+19.35% today · -43.0% 1Y
CanSino Biologics Inc. (SEHK: 6185) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.81B and employs 1,134 people.
Over the last twelve months the share price has lost 43.0%, trading between 19.22 and 56.55.
Tweenvest scores CanSino Biologics Inc. across four factors: quality 56/100, value 61/100, growth 100/100. Its strongest factor is growth.
6185 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.81B
- Revenue (TTM)
- $162.53M
- P/E
- —
- EPS
- -0.00
- Dividend yield
- —
- Beta (5Y)
- 1.21
- 52-week high
- HK$56.55
- 52-week low
- HK$19.22
- Avg volume (3M)
- —
- Shares outstanding
- 247.04M
- Employees
- 1,134
- Next earnings
- —
About CanSino Biologics Inc.
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. The company was incorporated in 2009 and is headquartered in Tianjin, the People’s Republic of China.
- ISIN
- CNE100003F01
- Founded
- 2009
- Listed since
- Mar 28, 2019
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $464.58B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $238.06B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $183.64B | $148.09 | -0.01% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.72B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $81.36B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $65.40B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $59.75B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.19B | AU$172.44 | -0.69% |
Figures last refreshed Aug 18, 2026.